Department of Molecular Cell Biology and Immunology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Boelelaan 1117, 1081 Amsterdam, The Netherlands.
Research Institute of Amsterdam Institute for Infection and Immunity, Inflammatory Diseases, 1105 Amsterdam, The Netherlands.
Int J Mol Sci. 2022 Sep 22;23(19):11132. doi: 10.3390/ijms231911132.
Patients with inflammatory bowel disease (IBD) produce enhanced immunoglobulin A (IgA) against the microbiota compared to healthy individuals, which has been correlated with disease severity. Since IgA complexes can potently activate myeloid cells via the IgA receptor FcαRI (CD89), excessive IgA production may contribute to IBD pathology. However, the cellular mechanisms that contribute to dysregulated IgA production in IBD are poorly understood. Here, we demonstrate that intestinal FcαRI-expressing myeloid cells (i.e., monocytes and neutrophils) are in close contact with B lymphocytes in the lamina propria of IBD patients. Furthermore, stimulation of FcαRI-on monocytes triggered production of cytokines and chemokines that regulate B-cell differentiation and migration, including interleukin-6 (IL6), interleukin-10 (IL10), tumour necrosis factor-α (TNFα), a proliferation-inducing ligand (APRIL), and chemokine ligand-20 (CCL20). In vitro, these cytokines promoted IgA isotype switching in human B cells. Moreover, when naïve B lymphocytes were cultured in vitro in the presence of FcαRI-stimulated monocytes, enhanced IgA isotype switching was observed compared to B cells that were cultured with non-stimulated monocytes. Taken together, FcαRI-activated monocytes produced a cocktail of cytokines, as well as chemokines, that stimulated IgA switching in B cells, and close contact between B cells and myeloid cells was observed in the colons of IBD patients. As such, we hypothesize that, in IBD, IgA complexes activate myeloid cells, which in turn can result in excessive IgA production, likely contributing to disease pathology. Interrupting this loop may, therefore, represent a novel therapeutic strategy.
炎症性肠病(IBD)患者产生的针对微生物群的免疫球蛋白 A(IgA)比健康个体要强,这与疾病严重程度相关。由于 IgA 复合物可以通过 IgA 受体 FcαRI(CD89)强烈激活髓样细胞,因此过多的 IgA 产生可能导致 IBD 病理学。然而,导致 IBD 中失调的 IgA 产生的细胞机制尚未得到很好的理解。在这里,我们证明了肠道 FcαRI 表达的髓样细胞(即单核细胞和中性粒细胞)与 IBD 患者固有层中的 B 淋巴细胞密切接触。此外,FcαRI 刺激单核细胞会触发细胞因子和趋化因子的产生,这些细胞因子和趋化因子调节 B 细胞分化和迁移,包括白细胞介素 6(IL6)、白细胞介素 10(IL10)、肿瘤坏死因子-α(TNFα)、增殖诱导配体(APRIL)和趋化因子配体 20(CCL20)。在体外,这些细胞因子促进了人 B 细胞的 IgA 同种型转换。此外,当幼稚 B 淋巴细胞在体外培养时,在 FcαRI 刺激的单核细胞存在下,与在未刺激的单核细胞存在下培养的 B 细胞相比,观察到增强的 IgA 同种型转换。总之,FcαRI 激活的单核细胞产生了细胞因子和趋化因子的混合物,刺激了 B 细胞的 IgA 转换,并且在 IBD 患者的结肠中观察到 B 细胞和髓样细胞之间的紧密接触。因此,我们假设在 IBD 中,IgA 复合物激活髓样细胞,这反过来又可能导致过度的 IgA 产生,可能导致疾病病理学。因此,中断这种循环可能代表一种新的治疗策略。